Latest News

STAT Plus: Pfizer’s top-selling vaccine won’t prevent Covid-19, but could get a boost because of it

Vaccines tend to get a bad reputation among biotech investors. Which makes it easy to forget that Pfizer’s top-selling product, with $5.8 billion in annual sales, is a vaccine: Prevnar 13.

Now Prevnar may be seeing a boost because of worries about the novel coronavirus, according to Umer Raffat, an analyst at Evercore ISI, an investment bank.

Continue to STAT Plus to read the full story…

Source link

Related posts

Fruit fly protein shows protective effect on dopamine-producing neurons


Depressed Workers Who Feel Support Miss Fewer Days


Is frequent digital media use linked to ADHD symptoms in teens?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World